Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Young

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Plos One|January 11, 2020
Oral misoprostol, low dose vaginal misoprostol, and vaginal dinoprostone for labor induction: Randomized controlled trialDavid C Young, Tina Delaney, B Anthony Armson, et al.
Inorganic Chemistry|September 26, 2017
An Isoreticular Series of Zinc(II) Metal-Organic Frameworks Derived from Terpyridylcarboxylate LigandsDavid C Young, Hui Yang, Shane G Telfer, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureusShveta Rani Singh, Alfred E Bacon, David C Young, et al.
Pediatric Pulmonology|September 18, 2020
Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosisQuovadis J Epps, Kevin L Epps, Jeffery T Zobell, et al.
Pediatric Pulmonology|September 11, 2019
Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosisMorgan T Ratté, Aubrey E Jones, Daniel M Witt, et al.
Pediatric Pulmonology|August 4, 2021
The indispensable role of pharmacy services and medication therapy management in cystic fibrosisJonathan J Grant, Erin J McDade, Jeffery T Zobell, et al.
Pediatric Pulmonology|March 3, 2021
State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summaryQuovadis J Epps, Kevin L Epps, David C Young, et al.
Pediatric Pulmonology|January 20, 2021
Understanding the expanding role of pharmacy services in outpatient cystic fibrosis careJeffery T Zobell, Justin Moss, Stephanie Heuser, et al.
Pediatric Pulmonology|October 15, 2019
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibioticsQuovadis J Epps, Kevin L Epps, David C Young, et al.
Pediatric Pulmonology|December 1, 2023
Venous thromboembolism management in people with cystic fibrosisAlan Abbinanti, Daniel M Witt, John Saunders, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Plos One|January 11, 2020
Oral misoprostol, low dose vaginal misoprostol, and vaginal dinoprostone for labor induction: Randomized controlled trialDavid C Young, Tina Delaney, B Anthony Armson, et al.
Inorganic Chemistry|September 26, 2017
An Isoreticular Series of Zinc(II) Metal-Organic Frameworks Derived from Terpyridylcarboxylate LigandsDavid C Young, Hui Yang, Shane G Telfer, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureusShveta Rani Singh, Alfred E Bacon, David C Young, et al.
Pediatric Pulmonology|September 18, 2020
Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosisQuovadis J Epps, Kevin L Epps, Jeffery T Zobell, et al.
Pediatric Pulmonology|September 11, 2019
Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosisMorgan T Ratté, Aubrey E Jones, Daniel M Witt, et al.
Pediatric Pulmonology|August 4, 2021
The indispensable role of pharmacy services and medication therapy management in cystic fibrosisJonathan J Grant, Erin J McDade, Jeffery T Zobell, et al.
Pediatric Pulmonology|March 3, 2021
State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summaryQuovadis J Epps, Kevin L Epps, David C Young, et al.
Pediatric Pulmonology|January 20, 2021
Understanding the expanding role of pharmacy services in outpatient cystic fibrosis careJeffery T Zobell, Justin Moss, Stephanie Heuser, et al.
Pediatric Pulmonology|October 15, 2019
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibioticsQuovadis J Epps, Kevin L Epps, David C Young, et al.
Pediatric Pulmonology|December 1, 2023
Venous thromboembolism management in people with cystic fibrosisAlan Abbinanti, Daniel M Witt, John Saunders, et al.
Pageof 10